Status:
WITHDRAWN
Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Transfusion Related Complication
Liver Transplant
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
We will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the solid organ donor. These 20 patients will be compared to 20 historical matched controls with regards to al...
Eligibility Criteria
Inclusion
- \- Recipients 18 years or older.
- Deceased donor whole graft liver transplant recipients undergoing liver transplant starting 07/01/2020 and onwards at VUMC.
- ABO-matched recipient and donor.
- Donor Hb level \>/= 8 g/dL
- Recipients with negative ABO antibody screen
Exclusion
- \- Pediatric recipient.
- HBS Antigen+ donors
- HCV NAT+ donors
- Donors of A2 blood type
- Donors on oral anticoagulants (except for aspirin) over the past 3 days before organ procurement
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04383756
Start Date
December 1 2020
End Date
July 1 2021
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37205